When is the plasma free 3‑methoxytyramine test indicated?

When is Plasma Free 3-Methoxytyramine Testing Indicated?

Plasma free 3-methoxytyramine (3-MT) should be measured in all patients with suspected pheochromocytoma and paraganglioma (PPGL), particularly those with germline SDHD mutations, head and neck paragangliomas, or when metastatic disease is suspected.

Primary Indications

1. Patients with SDHD Germline Mutations

The most recent 2023 consensus guideline specifically recommends plasma 3-MT measurement alongside metanephrines for all patients with PPGL and germline SDHD pathogenic variants 1. This is critical because:

• Up to 30% of head and neck paragangliomas (HNPGLs) produce dopamine, detectable only through 3-MT elevation
• These tumors rarely elevate normetanephrine (only 2.3% show levels >2x upper reference limit)
• Elevated normetanephrine in SDHD patients more likely indicates extra-cranial paragangliomas

2. Head and Neck Paragangliomas (HNPGLs)

Plasma 3-MT is particularly valuable for HNPGLs 1, 2, 3:

• Increases diagnostic sensitivity from 22.1% to 50.0% when added to standard metanephrines 2
• Plasma 3-MT detects 28-35% of biochemically active HNPGLs that would otherwise be missed 3
• Critical caveat: Urinary 3-MT is NOT useful for HNPGLs, as urinary dopamine derives from renal DOPA decarboxylation, not tumor production 1

3. Suspected Metastatic PPGL

Include 3-MT when metastatic disease is suspected, as dopamine-producing tumors (detected by 3-MT) have higher metastatic potential, particularly in SDHB mutation carriers 1, 4.

4. When Standard Metanephrines Are Normal but Suspicion Remains High

While rare (7.69% of cases), some PPGLs present with normal metanephrines but elevated 3-MT 5. Consider 3-MT measurement when:

• Typical imaging findings suggest PPGL
• Previous PPGL history exists
• Chromogranin A is elevated
• Clinical symptoms are highly suggestive

Testing Protocol Requirements

For accurate 3-MT measurement, blood must be drawn after overnight fasting 6, 4. This is non-negotiable because:

• Dietary considerations significantly affect 3-MT levels
• Food intake can cause false-positive elevations
• This requirement does NOT apply to normetanephrine/metanephrine alone

Additionally, patients should be supine for 30 minutes before sampling to minimize false-positives 6.

Diagnostic Performance

When properly collected, plasma 3-MT adds meaningful diagnostic value 2:

• Increases overall PPGL detection sensitivity from 97.2% to 98.6%
• More importantly, increases HNPGL detection from 22.1% to 50.0%
• Increases proportion of patients with highly predictive multiple metabolite elevations from 49.3% to 70.9%
• Maintains high specificity (95.1%)

Important Caveats and Pitfalls

Medication Interference

Norepinephrine reuptake blockers (NRBs) significantly elevate 3-MT levels 7:

• This occurs in a dose-dependent manner
• Antipsychotics and nicotine also independently increase 3-MT
• Consider discontinuing NRBs before testing when clinically safe
• If discontinuation impossible, interpret elevated 3-MT cautiously

Laboratory Method Matters

Use liquid chromatography with mass spectrometry (LC-MS/MS) for 3-MT measurement 6, 4. This method offers:

• Superior specificity over immunoassays
• Better sensitivity for low concentrations
• Reduced interference from medications

When NOT to Measure 3-MT

Do not routinely add 3-MT to screening in:

• Low-risk patients without SDHD mutations
• Patients where fasting blood draw is impractical (use urinary fractionated metanephrines instead)
• Initial screening at non-specialist centers (standard metanephrines suffice for most PPGLs)

Clinical Decision Algorithm

1. Start with plasma or urinary fractionated metanephrines for all suspected PPGL 6

2. Add plasma 3-MT when:

   • SDHD mutation confirmed or suspected
   • Head/neck location suspected or confirmed
   • Metastatic disease possible
   • Standard metanephrines normal but suspicion high

3. Ensure proper collection:

   • Overnight fast (mandatory for 3-MT)
   • 30 minutes supine rest
   • Review medications (especially NRBs, antipsychotics)

4. Interpret results:

   • Use age-adjusted reference intervals
   • Upper cut-off: 0.10 nmol/L for 3-MT 2
   • Consider medication effects if borderline elevated

The 2023 SDHD guideline represents the most current expert consensus, making plasma 3-MT measurement a Grade 1 recommendation (strong) for this specific population 1. For general PPGL screening, the 2014 Endocrine Society guideline establishes metanephrines as primary tests 6, with 3-MT serving as an important adjunct in the specific scenarios outlined above.